6 Results for "

hematological malignant cells

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "hematological malignant cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P9976
CAS No.: 1461640-62-9
Synonyms: ch38SB19; hu38SB19; SAR-650984

Target:  

CD38 Apoptosis

Research Areas:  

Cancer

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
loading...
    loading...
Cat. No.: HY-128601
CAS No.: 2097252-39-4
Purity:  99.79%
Research Areas:  

Cardiovascular Disease Cancer

CHK1-IN-3 is a potent and selective CHK1 inhibitor with an IC50 of 0.4 nM. CHK1-IN-3 effectively inhibits the growth of malignant hematopathy cell lines and displays low affinity for hERG (IC50 > 40 μM). CHK1-IN-3 significantly suppresses the tumor growth in vivo. CHK1-IN-3 can be used for the study of hematologic malignancies .
loading...
    loading...
Cat. No.: HY-175036
Research Areas:  

Cancer

YTHu78 is a KDM5B PROTAC degrader. YTHu78 induces KDM5B degradation via the ubiquitin-proteasome system and CRBN E3 ligase, and triggers lytic apoptosis in hematologic malignant cells. YTHu78 can be used in studies related to hematologic malignancies .
loading...
    loading...
Cat. No.: HY-180836
Research Areas:  

Cancer

DIX-01 is a molecular gel degrader that can simultaneously induce the degradation of IKZF1/3 and GSPT1 mediated by CRBN. Its DC50 values are: IKZF1 (19.80 nM), IKZF3 (45.31 nM), and GSPT1 (120.1 nM). DIX-01 exhibits nanomolar-level potent anti-proliferative activity in various cancer cell lines. DIX-01 induces apoptosis in MV4-11 cells and significantly inhibits the growth of leukemia cells in zebrafish. DIX-01 can be used for the study of malignant hematological tumors .
loading...
    loading...
Cat. No.: HY-P11815
CAS No.: 1227627-77-1
Target:  

Peptides

Research Areas:  

Cancer

TMTP1 is a five-amino acid (NVVRQ) tumor-homing peptide. TMTP1 slows the growth of tumor cells. TMTP1 serves as a diagnostic marker for hematological malignancies and acts as an anticancer drug carrier to enhance the cellular uptake rate of nanocarriers in tumor tissues. TMTP1 is applicable to research related to hematological malignancies, lymphoma, chronic myeloid leukemia, cervical cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-L079
4,276 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 4,276 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.